SkylineDx Expands Direct U.S. Commercial and Clinical Investment to Accelerate Access to Merlin™ CP-GEP

Summary

SkylineDx completed its transition from third-party commercialization to an integrated U.S. commercial model, establishing a dedicated sales, marketing and clinical organization of over 25 professionals across key U.S. markets to accelerate access to Merlin™ CP-GEP.